This is not a notice of funding opportunity (NOFO).

An estimated 1 in 8 U.S. adults have taken a Glucagon-like peptide-1 receptor agonist (GLP-1). Users often receive higher doses, which may increase gastrointestinal side effects and alter dietary intake, digestion, and nutrient absorption. As the usage of GLP-1s and understudied “GLP-1 mimicking” supplements grow, concerns about users’ nutritional status and the role of nutrient-containing dietary supplements in addressing potential nutrition gaps are increasingly important. This topic encourages research on the interaction of GLP-1s and nutrient metabolism and status, and population health. Research is also encouraged on roles of dietary supplements in addressing nutrient gaps that may arise with GLP-1 use, as well as on the composition, safety, and usage patterns, and biological mechanisms of supplements marketed to mimic GLP-1 activity. Participating Institutes and Centers include NIDDK* and NIA. NIDDK supports basic and clinical research on GLP-1–based therapies for weight loss and treatment of diabetes and its complications, and metabolic, digestive, liver, urologic and kidney diseases in children, adolescents, and adults. NIA supports research on the effects of GLP-1–based therapies across the aging spectrum, safety, efficacy, physiological, cognitive, and societal impacts.

*NIDDK may give special consideration to support meritorious applications in this topic area.

Expires April 24, 2028.